文献速递艾滋病与性传播感染结核与非结核分枝杆菌病毒性肝炎

HIV感染者孕期及产后异烟肼预防治疗的肝毒性

Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics.
PubMed 文献 · Clin Infect Dis · 2026-01-01

TB APPRISE(IMPAACT P1078)IV期随机多国非劣效试验纳入945名接受抗逆转录病毒治疗的孕产妇,比较孕期立即启动与产后第12周延迟启动28周异烟肼预防治疗的肝毒性。共63例(6%)发生肝毒性事件,仅5例(8%)发生于孕期,49例(78%)发生于分娩至产后24周;依非韦伦组中两研究组无差异,奈韦拉平立即组风险更高,慢代谢者风险增加。

要点

  • 肝毒性事件主要发生于产后早期,孕期少见
  • 依非韦伦治疗者中立即与延迟IPT的肝毒性无差异
  • 奈韦拉平使用者立即启动IPT时肝毒性风险更高

核心结论

  • 产后早期肝毒性风险高于孕期,需重点监测;选择IPT启动时机时应考虑抗逆转录病毒方案与药物基因组学。

研究设计与样本

  • TB APPRISE(IMPAACT P1078)为IV期随机、多国非劣效试验,比较孕期立即启动与产后第12周延迟启动28周异烟肼预防治疗的安全性;纳入945名有随访肝功能检测的妊娠HIV感染者,均在接受抗逆转录病毒治疗(85%使用依非韦伦,13%使用奈韦拉平)。

主要发现

  • 945名参与者中63例(6%)发生肝毒性事件,立即组29例(6%),延迟组34例(7%);仅5例事件(8%)发生于孕期,49例(78%)发生于分娩至产后24周之间。
  • 奈韦拉平使用者在立即组观察到更高的肝毒性风险;依非韦伦使用者中两组间无差异。
  • 慢效依非韦伦代谢者肝毒性风险增加。

关键数值与推荐

  • 肝毒性定义:肝酶升高≥3级;或肝酶升高≥2级伴胆红素升高或症状性肝炎。

临床怎么用

  • 产后早期应监测肝毒性,因该时期风险高于孕期;决定孕期及产后人群IPT启动时机时,应考虑抗逆转录病毒方案与药物基因组学。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: TB APPRISE (IMPAACT P1078), a Phase IV randomized, multi-country non-inferiority trial assessing the safety of 28 weeks of isoniazid preventive therapy (IPT) initiated during pregnancy (immediate IPT) versus deferring to week 12 postpartum (deferred IPT) in people with HIV on antiretroviral therapy, showed higher than expected hepatotoxicity. We investigated the potential roles of antiretrovirals, isoniazid, pharmacogenetics and other factors. METHODS: Hepatotoxicity was defined as Grade ≥3 liver enzyme elevations; or Grade ≥2 enzyme elevations with elevated bilirubin or symptomatic hepatitis. We performed Poisson regression of all-cause hepatotoxicity on study arm, antiretroviral regimen, pharmacogenetics of isoniazid and efavirenz metabolism (NAT2, CYP2B6) and other participant characteristics. Adjusted models included study arm and covariates with P < .25 in unadjusted models. Antiretroviral regimen and pharmacogenetics interactions with study arm were evaluated. RESULTS: All 945 pregnant participants with follow-up liver function measurements were on antiretrovirals (85% with efavirenz, 13% with nevirapine); 63 (6%) experienced hepatotoxicity events; 29 (6%) in immediate, and 34 (7%) in deferred arm; only 5 events (8%) occurred in pregnancy; 49 (78%) occurred between delivery and 24 weeks postpartum. Higher risk of hepatotoxicity was observed with nevirapine use in the immediate arm, but there was no difference by study arm in participants on efavirenz. Slow efavirenz metabolizers had increased risk of hepatotoxicity. CONCLUSIONS: It is critical to monitor for hepatotoxicity in early postpartum, where there is higher risk compared to antepartum. ARV regimen and pharmacogenetics should also be considered in making decisions on when to initiate IPT in pregnant and postpartum populations.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Montepiedra G, Aaron L, Theron G, et al. Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics. Clin Infect Dis. 2026. PMID: 40237651. doi:10.1093/cid/ciaf198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。